biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Prothena

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 14, 2020 2:13pm

250 Views

Post# 32101278

RE:Prothena

AlfredSisley, go read the XOMA 10K and Bioasis' reports and PRs, for goodness sakes. YES, PROTHENA SHOULD BE, MUST BE, AND WILL BE CONTAINED WITHIN BIOASIS' REPORTING.

Nobody likes tax loss selling. Nobody likes a 28¢ share price. Very few will buy from the offer in December. (No offense, just business.)

Shareholder meltdowns are born of ignorance about Bioasis and xB3. They are irrational, damaging and very unbecoming.

Get some visions of sugar plums dancing in your heads.

Your right jolly old elf,

jd

<< Previous

Bullboard Posts

Next >>

Buzz on the Bullboards: Stocks to watch in volatile times.